Our science
Mesenkia was founded 2024 on a scientific foundation from a long-standing Japanese-Swedish research collaboration, with the intention to develop treatments to cure the aggressive brain tumor, glioblastoma. The research resulted in Mesenkia’s proprietary KITAIbodies® that have the capacity to reshape how the field approaches targeted therapy in terminal cancers
Image created in https://BioRender.com
Target biology
The HVEM receptor is overexpressed on the glioblastoma tumor cells, including the cancer stem cells. Via HVEM’s capacity to bind APRIL, the tumor cells receive signals, enabling growth and aggressive behavior. Via the HVEM-BTLA interaction, the tumor can also evade the immune cells, an important driver in tumor pathogenesis.